These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22788917)

  • 1. New AMPA antagonists in epilepsy.
    Russo E; Gitto R; Citraro R; Chimirri A; De Sarro G
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1371-89. PubMed ID: 22788917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors in epilepsy.
    Citraro R; Aiello R; Franco V; De Sarro G; Russo E
    Expert Opin Ther Targets; 2014 Mar; 18(3):319-34. PubMed ID: 24387310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy.
    Faught E
    Expert Opin Investig Drugs; 2014 Jan; 23(1):107-13. PubMed ID: 24147649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures.
    Rektor I
    Expert Opin Pharmacother; 2013 Feb; 14(2):225-35. PubMed ID: 23259931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery and development of perampanel for the treatment of epilepsy.
    Hanada T
    Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel.
    Zaccara G; Giovannelli F; Cincotta M; Iudice A
    Expert Rev Neurother; 2013 Jun; 13(6):647-55. PubMed ID: 23739002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPA receptors in epilepsy and as targets for antiepileptic drugs.
    Rogawski MA; Donevan SD
    Adv Neurol; 1999; 79():947-63. PubMed ID: 10514878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perampanel for epilepsy with partial-onset seizures: a pharmacokinetic and pharmacodynamic evaluation.
    Schulze-Bonhage A
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1329-37. PubMed ID: 26111428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models.
    Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM
    J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging drugs for focal epilepsy.
    Mula M
    Expert Opin Emerg Drugs; 2013 Mar; 18(1):87-95. PubMed ID: 23176519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives.
    Di Bonaventura C; Labate A; Maschio M; Meletti S; Russo E
    Expert Opin Pharmacother; 2017 Nov; 18(16):1751-1764. PubMed ID: 29023170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of perampanel in epilepsy.
    Satlin A; Kramer LD; Laurenza A
    Acta Neurol Scand Suppl; 2013; (197):3-8. PubMed ID: 23480150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist.
    Patsalos PN
    Epilepsia; 2015 Jan; 56(1):12-27. PubMed ID: 25495693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic combinations of anticonvulsant agents: what is the evidence from animal experiments?
    Jonker DM; Voskuyl RA; Danhof M
    Epilepsia; 2007 Mar; 48(3):412-34. PubMed ID: 17346245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma.
    Löscher W; Schmidt D
    Epilepsia; 2011 Apr; 52(4):657-78. PubMed ID: 21426333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore modeling as an efficient tool in the discovery of novel noncompetitive AMPA receptor antagonists.
    Barreca ML; Gitto R; Quartarone S; De Luca L; De Sarro G; Chimirri A
    J Chem Inf Comput Sci; 2003; 43(2):651-5. PubMed ID: 12653534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular insights into the role of AMPA receptors in the synaptic plasticity, pathogenesis and treatment of epilepsy: therapeutic potentials of perampanel and antisense oligonucleotide (ASO) technology.
    Charsouei S; Jabalameli MR; Karimi-Moghadam A
    Acta Neurol Belg; 2020 Jun; 120(3):531-544. PubMed ID: 32152997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and anticonvulsant evaluation of N-substituted isoquinoline AMPA receptor antagonists.
    Gitto R; De Luca L; Pagano B; Citraro R; De Sarro G; Costa L; Ciranna L; Chimirri A
    Bioorg Med Chem; 2008 Mar; 16(5):2379-84. PubMed ID: 18077172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and development of 2,3-benzodiazepine (CFM) noncompetitive AMPA receptor antagonists.
    Gitto R; Zappal M; De SG; Chimirri A
    Farmaco; 2002 Feb; 57(2):129-34. PubMed ID: 11902655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.